Prevention of Complications of Secondary Hyperparathyroidism in Long-Term Dialysis Patients

2015 ◽  
pp. 58-61
Author(s):  
L. Bignardi ◽  
V. Cambi ◽  
F. Bono ◽  
F. Gardini ◽  
P. Zanelli
Keyword(s):  
Secondary Hyperparathyroidism ◽  
Dialysis Patients

scholarly journals Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism

2015 ◽  
Vol 87 (4) ◽  
pp. 846-856 ◽  
Author(s):  
Geert J. Behets ◽  
Goce Spasovski ◽  
Lulu R. Sterling ◽  
William G. Goodman ◽  
David M. Spiegel ◽  
...  
Keyword(s):  
Secondary Hyperparathyroidism ◽  
Bone Histomorphometry ◽  
Term Treatment ◽  
Dialysis Patients ◽  
Long Term Treatment ◽  
Before And After

Alterations in serum phosphate levels predict the long-term response to intravenous calcitriol therapy in dialysis patients with secondary hyperparathyroidism

2008 ◽  
Vol 26 (2) ◽  
pp. 185-190 ◽  
Author(s):  
Kiyoko Hosaka ◽  
Junichiro James Kazama ◽  
Suguru Yamamoto ◽  
Yumi Ito ◽  
Noriaki Iino ◽  
...  
Keyword(s):  
Secondary Hyperparathyroidism ◽  
Serum Phosphate ◽  
Dialysis Patients ◽  
Term Response

Practical use of parenteral calcimimetics for severe secondary hyperparathyroidism. A case report

2021 ◽  
Vol 2 (3(5)) ◽  
pp. 58-62
Author(s):  
S.E. Khoroshilov ◽  
◽  
S.V. Besedin ◽  
A.V. Nikulin ◽  
◽  
...  
Keyword(s):  
Clinical Trials ◽  
Case Report ◽  
Secondary Hyperparathyroidism ◽  
Cardiovascular Complications ◽  
Treatment Session ◽  
Dialysis Patients ◽  
Calcium Sensing Receptor ◽  
Serum Parathyroid Hormone ◽  
Calcium Sensing

Secondary hyperparathyroidism (SHPT) leads to bone disorders and cardiovascular complications in long-term dialysis patients. SHPT is caused by hyperphosphatemia. Abnormalities of calcium-sensing receptor (CaSR) are associated with the pathogenesis of SHPT. Clinical trials have shown that calcimimetics significantly reduce the risks of parathyroidectomy, bone fracture and cardiovascular hospitalization among long-term dialysis patients with SHPT. Etelcalcetide, a novel calcimimetic compound, acts as a direct CaSR agonist, restores the sensitivity of the CaSR in parathyroid cells, and decreases serum parathyroid hormone without inducing hypercalcemia or hyperphosphatemia. Etelcalcetide's properties allow it to be administered intravenously thrice weekly at the end of a hemodialysis treatment session improving medication adherence.

scholarly journals Long-term effectiveness of cinacalcet in non-dialysis patients with chronic kidney disease and secondary hyperparathyroidism

2019 ◽  
Vol 38 (2) ◽  
pp. 229-238 ◽  
Author(s):  
Ariadna Pérez-Ricart ◽  
Maria Galicia-Basart ◽  
Dolors Comas-Sugrañes ◽  
Josep-Maria Cruzado-Garrit ◽  
Alfons Segarra-Medrano ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Secondary Hyperparathyroidism ◽  
Dialysis Patients

scholarly journals The effect of long-term intravenous calcitriol administration on parathyroid function in hemodialysis patients.

1991 ◽  
Vol 2 (5) ◽  
pp. 1014-1020 ◽  
Author(s):  
M Rodriguez ◽  
A J Felsenfeld ◽  
C Williams ◽  
J A Pederson ◽  
F Llach
Keyword(s):  
Secondary Hyperparathyroidism ◽  
Hemodialysis Patients ◽  
Parathyroid Cell ◽  
Dialysis Patients ◽  
Prolonged Administration ◽  
Set Point ◽  
Parathyroid Function ◽  
Before And After ◽  
Pth Level

Secondary hyperparathyroidism is common in dialysis patients. Intravenous calcitriol has proven to be an effective therapy for the reduction of parathyroid hormone (PTH) levels. However, the effect of i.v. calcitriol on parathyroid function, defined as the sigmoidal PTH-calcium curve developed during hypocalcemia and hypercalcemia, has not been evaluated during the prolonged administration of i.v. calcitriol. Six hemodialysis patients with marked secondary hyperparathyroidism, PTH levels greater than 500 pg/mL (normal, 10 to 65 pg/mL), were treated for 42 wk with 2 micrograms of i.v. calcitriol after each hemodialysis. Parathyroid function was evaluated before and after 10 and 42 wk of calcitriol therapy. Between baseline and 42 wk, the basal PTH level decreased from 890 +/- 107 to 346 +/- 119 pg/mL (P less than 0.02) and the maximally stimulated PTH level decreased from 1293 +/- 188 to 600 +/- 140 pg/mL (P less than 0.01). In addition, calcitriol administration significantly decreased PTH levels throughout the hypocalcemic range of the PTH-calcium curve. Although the slope of the PTH-calcium curve (with maximal PTH as 100%) decreased between baseline and 42 wk (P less than 0.05), the set point of calcium did not change. Two patients with a decrease in both basal and maximally stimulated PTH levels after 10 wk of calcitriol, developed marked hyperphosphatemia between 10 and 42 wk; this resulted in an exacerbation of hyperparathyroidism despite continued calcitriol therapy. In conclusion, prolonged i.v. calcitriol administration is an effective treatment for secondary hyperparathyroidism in hemodialysis patients provided that reasonable control of the serum phosphate is achieved. In addition, the slope of the PTH-calcium curve may be a better indicator of parathyroid cell sensitivity than the set point of calcium.

scholarly journals Hypocalcemic cardiomyopathy after parathyroidectomy in a patient with uremia: A case report and literature review

2020 ◽  
Vol 48 (7) ◽  
pp. 030006052094211
Author(s):  
Wei Zhang ◽  
Feng Xue ◽  
Quandong Bu ◽  
Xuemei Liu
Keyword(s):  
Heart Failure ◽  
Case Report ◽  
Secondary Hyperparathyroidism ◽  
Calcium Supplementation ◽  
Severe Heart Failure ◽  
Cardiac Complications ◽  
Refractory Heart Failure ◽  
First Case ◽  
Insight Into

Hypocalcemia is a rare, but reversible, cause of dilated cardiomyopathy. Although cardiomyopathy may cause severe heart failure, calcium supplementation can reverse heart failure. We report here a patient with uremia and secondary hyperparathyroidism, who was complicated by persistent hypocalcemia and refractory heart failure. The cardiac failure was refractory to treatment with digitalis and diuretics, but dramatically responded to calcium therapy and restoration of normocalcemia. As a result, the patient was eventually diagnosed with hypocalcemic cardiomyopathy. To the best of our knowledge, this is the first case of this disease to be reported in a patient with uremia. Findings from our case may help clinicians to better understand hypocalcemic cardiomyopathy. Our case might also provide new insight into long-term cardiac complications and prognoses of patients undergoing parathyroidectomy due to secondary hyperparathyroidism.

scholarly journals SP507FACTORS AFFECTING LONG TERM TECHNIQUE SURVIVAL OF PERITONEAL DIALYSIS PATIENTS

2015 ◽  
Vol 30 (suppl_3) ◽  
pp. iii546-iii547
Author(s):  
Marios Theodoridis ◽  
Stylianos Panagoutsos ◽  
Eleni Triantafyllidou ◽  
Pelagia Kriki ◽  
Konstantia Kantartzi ◽  
...  
Keyword(s):  
Peritoneal Dialysis ◽  
Dialysis Patients ◽  
Technique Survival
Sign in / Sign up

Export Citation Format

Share Document